← Leaderboards
Xiumei Huang
Indiana University Indianapolis
$4,132,015
Attributed
$4,692,488
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.2M · FY2019–24$2M$1.5M$1M$500K$0
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$4,692,488 · 3
By mechanism
R01$4,692,488 · 3
Top collaborators
- Edward Ayson Motea3 shared
Most similar at Indiana University Indianapolis
Same institution · by research overlap
- Roland W. Herzog$25,146,618
- Jing Ma$543,404
- Bryan Paul Schneider$1,500,312
- Edward Ayson Motea$1,677,769
- Xinna Zhang$3,467,211
Others in their field
Other Emerging Leaders on “Malignant Neoplasms”
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
- Leonard Freedmand · Leidos Biomedical Research, Inc.$108,968,336
- Beverly Hayes · Leidos Biomedical Research, Inc.$98,336,166
- Martha Hering · Westat, Inc.$57,098,843
Research focus
Malignant NeoplasmsOxidoreductasePharmaceutical PreparationsQuinonesTumorEnzymesBeta-LapachoneTargeted TreatmentIn VivoCellsMediatingCancer CellNecrosisNqo1 GeneSynergismNeoplastic CellDna DamageResponseResistanceElectronsProductionCancer TherapyMetabolicNon-Small-Cell Lung Carcinoma
Grant awards (12)
Targeting NQO1+ tumor to trigger innate and adaptive immunity$427,984
R01 · FY2024 · CA · contact PI
Targeting NQO1+ tumor to trigger innate and adaptive immunity$441,498
R01 · FY2023 · CA · contact PI
Targeting NQO1+ tumor to trigger innate and adaptive immunity$450,508
R01 · FY2022 · CA · contact PI
Tumor-selective use of PARP inhibitors against NQO1+ nonsmall cell lung cancer$356,044
R01 · FY2022 · CA · contact PI
Tumor-selective radiosensitization of NSCLC using NQO1 bioactivatable drugs$353,076
R01 · FY2022 · CA · contact PI
Targeting NQO1+ tumor to trigger innate and adaptive immunity$407,082
R01 · FY2021 · CA · contact PI
Tumor-selective use of PARP inhibitors against NQO1+ nonsmall cell lung cancer$381,823
R01 · FY2021 · CA · contact PI
Tumor-selective radiosensitization of NSCLC using NQO1 bioactivatable drugs$360,281
R01 · FY2021 · CA · contact PI
Targeting NQO1+ tumor to trigger innate and adaptive immunity$421,360
R01 · FY2020 · CA · contact PI
Tumor-selective use of PARP inhibitors against NQO1+ nonsmall cell lung cancer$383,079
R01 · FY2020 · CA · contact PI
Tumor-selective radiosensitization of NSCLC using NQO1 bioactivatable drugs$360,281
R01 · FY2020 · CA · contact PI
Tumor-selective radiosensitization of NSCLC using NQO1 bioactivatable drugs$349,472
R01 · FY2019 · CA · contact PI